Label Free Detection Market

Report Overview

The global label free detection market was valued at US$ 6.0 billion in 2021 and is expected to witness a CAGR of 15% during the forecast period from 2022 to 2030.

Market Fundamentals

The term "label-free detection systems" refers to integrated systems used to study biomolecular interactions without reducing the labels or causing autofluorescence. These technologies enable the rapid and real-time discovery of novel medications. Label-free detection methods are used to detect biochemical and cell-based assays. The label-free detection technique is used to detect biomolecules and their interactions. This method has shown to be an excellent research and development tool for the biotech and pharmaceutical industries. The market will grow as a result of collaborations between pharmaceutical companies and academic institutions, as well as an increase in drug discovery programs. Label-free technology enables researchers to conduct studies using novel methodologies that solely provide end-point results. Labels have the potential to introduce items by inactivating or reducing the ability of the biomolecule of interest to interact. 

[36236734]

Market Dynamics 

The expanding R&D activities in the pharmaceutical and biotechnology fields are propelling the global label-free detection market. Label free detection techniques are in great demand due to an increase in outsourcing pharmaceutical activities and R&D activities by academic institutions. Because they effectively manage the complexity of various signaling pathways, these approaches are in high demand. Furthermore, label free detection approaches avoid the use of autofluorescence and spatial interference, increasing their acceptance. Furthermore, the market is predicted to rise as a result of joint efforts by governments and private groups to hold seminars and raise awareness among end-users about the benefits of employing label-free detection techniques. In addition to the current situation, firms' continuous efforts to develop cutting-edge label free detecting techniques will help the industry flourish.

Market Ecosystem 

The global label free detection market has been analyzed from four perspectives: Technology, Products, Application and Region. 

Label Free Detection Market by Technology

[5234155]

Based on technology, the global label free detection market is segmented into cellular dielectric spectroscopy, bio-layer interferometry, surface plasmon resonance, and optical waveguide grating technology. The surface plasma resonance dominated the market during the forecast period. Furthermore, the same segment is predicted to have the greatest CAGR in the market. This expansion is due to the technology's high sensitivity and widespread application in adjusting specificity, affinity, and kinetic parameters during macromolecule binding.

Label Free Detection Market by Products

Based on products, the global label free detection market has been segmented into instruments, consumables, biosensor chips, microplates. The consumables segment dominated the market during forecast period owing to the factors such as continuing breakthroughs in label free detection technologies and high consumption volumes in biopharmaceutical and biotechnology sectors.

Label Free Detection Market by Application 

Based on application, the global label free detection systems have been segmented into binding thermodynamics, binding kinetics, hit confirmation, lead generation. The binding kinetics segment dominated the market during the forecast period due to the rising demand for medications with a broad therapeutic index, advances in structural biology, and increased R&D activities to detect coronavirus using a label free detection approach.

Label Free Detection Market by Region

Based on regions, the global label free detection market have been segmented into North America, Europe, Asia Pacific and the Rest of the World. North America dominated the global label free detection market in 2021. Positive regulatory and political conditions, an ever-increasing number of local biotech enterprises, and expanding demand for innovative biopharmaceuticals have all contributed to the rise in demand for label free detection devices. The trend is projected to continue due to the market's significant quantity of catch-up potential and the increased availability of biotech drugs. Increased funding for academic and public-sector research institutes is also driving demand for label free products in North America. 

Moreover, the Asia Pacific is the fastest-growing region in the global label free detection market. Asian countries like China and India are predicted to expand at the fastest rates. Strict regulatory requirements in various industries are driving demand for sample analysis and quality control tools. Furthermore, investments in laboratory infrastructure are becoming increasingly appealing, particularly in China. Regional market growth is likely driven by government-supported efforts to stimulate innovation in healthcare industries. For the first time in 2021, China invested more in research and development than the United States, increasing its proportion of R&D spending.

Competitive Landscape 

Some of the prominent market players in the global label free detection systems include:

• Danaher Corporation
• GE Healthcare
• F. Hoffmann-La Roche Ltd.
• PerkinElmer Inc.
• Horiba Ltd.
• Agilent Technologies, Inc.
• Mettler Toledo
• Corning Inc.
• Bioptix Inc.
• BioNavis Limited 
• Attana AB

Manufacturers continue pushing the bounds of sensitivity and throughput as knowledge of the benefits of label-free detection grows. Key market players are accelerating their R&D initiatives to produce unique products to achieve considerable growth in existing and new business categories. It also focuses on improving its position in key markets by introducing new product offerings.

Strategic Development 

• In March 2021, Sartorius' Life Science Group unveiled the revolutionary high-performance Octet® R range of systems, the company's most recent update to its line of label free analytical tools. Users will be able to find the right balance between throughput requirements and their financial goals with three distinct models.
• In October 2020, HORIBA announced the ADS EVO automatic driving system, a driving robot for automobile testing. The ADS EVO improves vehicle testing effectiveness by lowering the number of repeat tests, laboratory running expenses, total test time, and the number of human errors.
• In July 2020, Hitachi Ltd. partnered with ThinkCyte Inc. to create an artificial intelligence (AI)-powered cell analysis and sorting system. With this agreement, the companies hope to combine ThinkCyte Inc.'s high-throughput technology with Hitachi Ltd.'s label-free single-cell sorting expertise to create large-scale devices.
• In March 2020, Danaher Corporation finalized the acquisition of General Electric Company's life sciences division's Biopharma unit. The purchased company, Cytiva, would operate as a separate entity under Danaher Corporation's biosciences division.

Frequently Asked Questions About This Report